Flumatinib

DRUG8 trials

Conditions

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic Leukemia, Adult B-CellAcute Myeloid LeukemiaBCR-ABL1 Fusion Protein ExpressionCML, Chronic PhaseCML-CP; Mutation;Suboptimal Response or Failure in TKIChronic Myeloid Leukemia

Phase 2

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

NCT01503502

Jiangsu HengRui Medicine Co., Ltd.Myelogenous Leukemia, Chronic

Start: 2011-08-31End: 2014-12-31Updated: 2013-04-10

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

CompletedNCT05433532

The First Affiliated Hospital of Soochow UniversityAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia +2

Start: 2022-05-01End: 2024-04-13Updated: 2024-04-25

Phase 3

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

NCT04375683

Zhongda HospitalAcute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression

Start: 2020-03-01End: 2022-12-30Target: 28Updated: 2022-03-24

Phase 4

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

NCT04677439

Shenzhen Second People's HospitalChronic Myeloid Leukemia, Chronic Phase, Flumatinib, Imatinib

Start: 2021-01-01End: 2023-12-30Target: 200Updated: 2022-03-16

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

NCT04933526

Shenzhen Second People's HospitalChronic Myeloid Leukemia in Chronic Phase

Start: 2021-07-01End: 2023-06-30Target: 118Updated: 2022-07-27

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

TerminatedNCT05071482

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Leukemia

Start: 2021-09-16End: 2023-01-16Updated: 2025-05-01

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruitingNCT05367765

Jiangsu Hansoh Pharmaceutical Co., Ltd.CML, Chronic Phase

Start: 2022-04-30End: 2028-04-30Target: 2400Updated: 2022-05-10

Unknown Phase

Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

NCT04681820

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCML-CP; Mutation;Suboptimal Response or Failure in TKI